Eventide Asset Management’s Aktis Oncology AKTS Stock Holding History
Bought
Maintained
Sold
Other funds holding AKTS
Eventide Asset Management's AKTS Position: Q3 2026 in Review
Eventide Asset Management increased its Aktis Oncology (AKTS) stake by 110% in Q3 2026, buying an estimated $13.6M and bringing the position to 1,065,000 shares worth $20.7M. The position accounts for 0.29% of the portfolio, ranked #111.
Eventide Asset Management first reported a position in AKTS in Q1 2026 and has held it in 3 quarters since. 123 funds tracked by Wall St. Rank hold AKTS as of Q3 2026.
- Eventide Asset Management held 1,065,000 shares of Aktis Oncology worth $20.7M as of Q3 2026.
- Eventide Asset Management bought 558,000 Aktis Oncology shares in Q3 2026, an estimated $13.6M.
- Aktis Oncology made up 0.29% of Eventide Asset Management's portfolio in Q3 2026, its #111 holding.
- Eventide Asset Management first reported a position in Aktis Oncology in Q1 2026 and has held it in 3 quarters since.
- 123 funds tracked by Wall St. Rank held Aktis Oncology as of Q3 2026.
Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.